SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Seracare Life Sciences Inc – ‘NT 10-Q’ for 6/30/05

On:  Wednesday, 8/10/05, at 9:09am ET   ·   Effective:  8/10/05   ·   For:  6/30/05   ·   Accession #:  1193125-5-163370   ·   File #:  0-33045

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 8/10/05  Seracare Life Sciences Inc        NT 10-Q     6/30/05    1:30K                                    RR Donnelley/FA

Notice of a Late Filing of a Form 10-Q   —   Form 12b-25
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: NT 10-Q     Notification of Late Filing                         HTML     29K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  Notification Of Late Filing  

(Check one):

    ¨  Form 10-K

    ¨  Form 20-F

    ¨  Form 11-K

    x  Form 10-Q

    ¨  Form N-SAR

    ¨  Form N-CSR

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

OMB APPROVAL


OMB Number: 3235-0058


Expires: March 31, 2006


Estimated average burden Hours per response . . . 2.50


SEC FILE NUMBER

    0-25283


CUSIP NUMBER

    218868-10-7


 

    For Period Ended: June 30, 2005
    ¨  Transition Report on Form 10-K
    ¨  Transition Report on Form 20-F
    ¨  Transition Report on Form 11-K
    ¨  Transition Report on Form 10-Q
    ¨  Transition Report on Form N-SAR
    For the Transition Period Ended:                                                               

 

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:             

 


 

PART I — REGISTRANT INFORMATION

 

 

SeraCare Life Sciences, Inc.


Full Name of Registrant

 

N/A


Former Name if Applicable

 

1935 Avenida del Oro, Suite F


Address of Principal Executive Office (Street and Number)

 

Oceanside, California 92056


City, State and Zip Code

 


 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

x

  (a)   The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
  (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

SEC 1344 (07-03)   Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.



 

PART III — NARRATIVE

 

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The Company’s report on Form 10-Q for the period ended June 30, 2005 could not be filed within the prescribed time period because the Company experienced technical difficulties in connection with its transmission of the filing through the edgar system. Although the Company, through its financial printer, initiated the transmission prior to the filing deadline, as a result of the heavy volume of filings being submitted at that time, the Company has been advised that its filing was received by the SEC just after the filing deadline. The Company initiated its transmission just prior to the filing deadline as the Company was completing final edits to the Form 10-Q up to such time to reflect continuing discussions with its auditors. This delay could not be eliminated without unreasonable expense or effort.

 


 

PART IV— OTHER INFORMATION

 

(1)   Name and telephone number of person to contact in regard to this notification

 

Craig A. Hooson


(Name)

 

(760)


(Area Code)

  

806-8922


(Telephone Number)

 

(2)   Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).  Yes    x    No  ¨    

 

 

 

(3)   Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?    Yes  x    No  ¨    

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

Please see the Form 10-Q that was submitted by the Company for its fiscal quarter ended June 30, 2005.

 


 

 

SeraCare Life Sciences, Inc.


             (Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 10, 2005   By  

/s/ Craig A. Hooson


       

Craig A. Hooson

Chief Financial Officer

 

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

 

ATTENTION

 

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

 

 

GENERAL INSTRUCTIONS

 

1.    This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.
2.    One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the form will be made a matter of public record in the Commission files.
3.    A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class of securities of the registrant is registered.
4.    Amendments to the notifications must also be filed on Form 12b-25 but need not restate information that has been correctly furnished. The form shall be clearly identified as an amended notification.
5.    Electronic Filers: This form shall not be used by electronic filers unable to timely file a report solely due to electronic difficulties. Filers unable to submit reports within the time period prescribed due to difficulties in electronic filing should comply with either Rule 201 or Rule 202 of Regulation S-T (§232.201 or §232.202 of this chapter) or apply for an adjustment in filing date pursuant to Rule 13(b) of Regulation S-T (§232.13(b) of this chapter).

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘NT 10-Q’ Filing    Date    Other Filings
3/31/06
Filed on / Effective on:8/10/0510-Q,  8-K
For Period End:6/30/0510-Q
 List all Filings 
Top
Filing Submission 0001193125-05-163370   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 9, 12:43:18.1am ET